Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Depression Prevention in ACS
NCT02451293Phase 3Completed
- Sponsor
- Zealand University Hospital
- Start
- Jan 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melatonin in major depressive disorder (MDD), sponsored by Zealand University Hospital. Started Jan 2016; status: completed.
02
Drugs
melatonin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02451293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451293.